Cover Image
市場調查報告書

Celecoxib的中國市場

Investigation Report on China Celecoxib Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332765
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Celecoxib的中國市場 Investigation Report on China Celecoxib Market, 2010-2019
出版日期: 2015年06月11日 內容資訊: 英文 20 Pages
簡介

由GD Searle及Pfizer所開發的Celecoxib,在1999年以Celebrex這個商品名在市場上推出,自那之後便成了公譽抗風濕藥的No. 1品牌。Pfizer的製造商Celebrex在2009年9月通過CFDA(中國國家食品藥品監督管理局)核可上市後,在中國市場銷售量急速上升。2005年2000萬人民幣的銷售量到2014年已增加到1億6400萬人民幣的規模。

本報告提供中國的Celecoxib市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Celecoxib的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國Celecoxib的市場簡介

  • Celecoxib的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Celecoxib銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國Celecoxib的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國Celecoxib的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的Celecoxib的標準價格

  • Shire Plc (Celebrex)
  • Pfizer Inc (Celebrex)

第7章 中國市場中Celecoxib的主要製藥公司

  • Pfizer Inc
  • Shire Plc

第8章 中國Celecoxib的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506208

Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs cause gastrointestinal adverse reactions such as ulcer, perforation and bleeding. The latest research has shown that among all the NSAIDs, celecoxib reports the lowest number of cases of gastrointestinal side effects. As a kind of NASIDs, celecoxib is mainly used for osteoarthritis, rheumatoid arthritis and the adjuvant treatment of familial adenomatous polyposis. It is reported that over 100 million people in China suffer from arthritis, among which about 10% use celecoxib.

Developed by GD Searle & Pfizer, celecoxib came into the market in 1999 under the trade name of Celebrex. Ever since its debut in the US in Feb. 1999, celecoxib has been widely used and set a record for the largest amount of prescriptions among all the new drugs in that year. Celecoxib has become the No. 1 brand of anti-rheumatic drug with a reputation as the most successful branded drug in the market.

In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, annual sales rising from CNY 20 million in 2005 to CNY 164 million in 2014 and CAGR reaching up to 24.59% during the period of 2005-2014. Celecoxib enjoys a vast demand in China. Currently, celecoxib in the Chinese market mainly come from two companies: Pfizer Inc and Shire Plc. They monopolize the Chinese market and Pfizer has a larger market share of over 98%, sales value reaching up to CNY 162 million in 2014.

The market size of celecoxib is expected to keep expanding in China in the next few years.

Readers can get at least the following information from this report:

  • market size of celecoxib in China
  • market share of manufacturers of celecoxib in China
  • price of celecoxib in Chinese market
  • major manufacturers of celecoxib in Chinese market
  • market outlook of celecoxib in China

The author suggests the following groups of people purchase this report:

  • manufacturers of NSAIDs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Celecoxib

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Celecoxib in China

  • 2.1. Patent and Approval Status of Celecoxib in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Celecoxib in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.1. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Celecoxib in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Celecoxib in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Celecoxib in Chinese Hospitals in 2014

  • 6.1. Shire Plc (Trade Name: Celebrex)
  • 6.2. Pfizer Inc (Trade Name: Celebrex)

7. Major Manufacturers of Celecoxib in Chinese Market, 2010-2014

  • 7.1. Pfizer Inc
  • 7.2. Shire Plc

8. Market Outlook of Celecoxib in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Approval Information of Celecoxib in China
  • Chart Sales Status of Celecoxib in China
  • Chart Sales Value of Celecoxib in China, 2010-2014
  • Chart Sales Value of Celecoxib in Some Regions in China, 2010-2014
  • Chart Sales Volume of Celecoxib in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Celecoxib for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Celecoxib Made by Pfizer (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Celecoxib Made by Shire (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Celecoxib Capsules in China, 2010-2014
  • Chart Price of Celecoxib Made by Shire Plc (the US) in Some Chinese Cities in 2014
  • Chart Price of Celecoxib Made by Pfizer Inc (the US) in Some Chinese Cities in 2014
Back to Top